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Table 1. Patient characteristics.  
Heart failure is  a worldwide epidemic affecting approximately 23 million 
people globally and is a major burden for the healthcare system [1,2]. 
Despite advances in medical therapy, the disease is progressive and a 
significant proportion of patients will need advanced heart replacement 
therapy. 
Left ventricular assist devices (LVAD) are an invaluable part of the 
therapeutic measures for patients suffering from advanced heart failure. 
When used either as a bridge to transplant, to promote myocardial 
recovery, or as lifetime use, LVADs have proven to prolong survival and 
improve quality of life [1-3]. In spite of their success in improving 
mortality and quality of life, thrombotic and bleeding events remain 
significant complications [1]. Achieving therapeutic anticoagulation 
efficiently with warfarin is important to reduce thrombotic and bleeding 
risks and is influenced by genotype. 
Warfarin has a narrow therapeutic index and displays marked person-to-
person variation in dose requirement. Functional polymorphisms at 
candidate genes can therefore offer utility as biomarkers to individualize 
warfarin treatment.  
 Aim of the Study  
The main objective of this study was to determine frequency of 
polymorphisms in CYP2C9, VKORC1 in Kazakhstani patients with 
mechanical circulatory support - LVADs for further genome-guided 
anticoagulant therapy.  
The study is conducted in accordance with the rules and requirements 
of the Helsinki Declaration. Written informed consent was obtained from 
all patients included into the study. Research protocol was approved by 
the ethics committees of National Laboratory Astana, Nazarbayev 
University and National Research Center for Cardiac Surgery, Astana, 
Kazakhstan. 
           
Study population 
Implantation of LVADs in Kazakhstan is carried out since 2011 in JSC 
"National Research Center for Cardiac Surgery ", (NRCCS) Astana, 
Kazakhstan. 
All patients were unrelated Kazakhstani individuals treated in NRCCS, 
Astana, Kazakhstan due to heart failure. In total, 100 study participants 
(patients with implanted LVADs) were recruited in the study group during 
2011-2016. The control group consisted of 95 conditionally healthy 
individuals, corresponding to the patients group by sex, age and 
nationality. 
           
 DNA isolation and genotyping 
Genomic DNA was extracted from 200 μL whole blood using 
PureLinkTM Genomic DNA Mini Kit (Invitrogen, UK) according to 
manufacturer's standard protocol. The genomic DNA concentration was 
measured using NanoDrop™ Spectrophotometer (Thermo Fisher 
Scientific, USA) and adjusted to 10 ng/μl. 
Genotyping of polymorphisms VKORC1 and CYP2C9 genes were 
performed using RT PCR TaqMan Assay on 7900HT Fast Real-Time 
PCR System (Applied Biosystems, USA). We examined the VKORC1 
1639 G>A mutation, CYP2C9*2 (430 C>T; cytosine to thymine) and  the 
CYP2C9*3 (1075 A>C; adenine to cytosine) mutations. 
 
Data on the INR level achieved and the most representative warfarin 
dosage of the patients at discharge or before in-hospital MCS recovery, 
heart transplant, or Death were gathered. 
Data on the bleeding events for up to 18 months after MCS implant or 
before in-hospital MCS recovery, heart transplant, or death were 
evaluated.  
 
Patients were divided into two groups for analysis: patients with 
abnormal warfarin polymorphisms and patients without any 
polymorphisms. Mean warfarin dosage, mean reached INR, and the rate 
of bleeding events per patient-year were compared in these two groups. 
Demographic data on age, gender, height, weight, ethnicity, obesity, 
diabetes, hypertension, cardiomyopathy type, and MCS type were 
collected. We also examined any association between the mutation 
presence and the numerical variables of age, height, weight, and body 
mass index (BMI). Furthermore, multivariable analysis was performed to 
identify any significant predictors for the presence of any of the analyzed 
polymorphisms. 
 
Statistical Analysis 
Continuous variables were summarized by mean ± standard deviation. 
Normally distributed continuous variables were compared across the 
two patient groups by the independent samples t-test. Non normally  
distributed numerical variables were compared across the two groups 
by the Wilcoxon rank sum test. Categorical variables were summarized 
by frequency (%). Categorical variables were compared across groups 
by the Fisher exact test. P-value <0.05 was considered statistically 
significant. All statistical analyses were carried out using SPSS 21 
(SPSS Inc., Chicago, IL). 
Variables Subjects (n=100) 
Ethnicity:    Kazakh 
                    Russian 
                      Other 
78% 
16% 
6% 
Average age, years±SD 52,4±11,5 
Sex : Male 
        Female  
 93% 
7% 
Weight, kg (range)  79,7±14,0 (48 till 114) 
Height, cm (range) 169,9±6,4 (148 till 183) 
BMI, kg/m2 27,6±4,6 
Smoking, % 58% 
Heart Failure etiology: Ischemic genesis  
                                       Non ischemic 
44 % 
56 % 
Ischemic cardiomyopathy 44 % 
Dilated cardiomyopathy 42 % 
Hypertensive cardiomyopathy 9 % 
Valvular cardiomyopathy 4 % 
Arterial cardiomyopathy 1 % 
Type of implanted LVADs: 
HeartMateIII (Thoratec Corporation, USA) 
HeartMate II (HMII) (Thoratec Corporation, 
USA)  
HeartWare HVAD (HeartWare Inc., USA) 
  
46% 
35% 
 19% 
NYHA class: IIIА+ IIIB 
                       IV  
70% 
28% 
EF, % 21,7 (9 - 41) 
LV EDD, mm 70,2 (38 - 88)  
Pulse, beats per minute 85,4±17,2 
Systolic blood pressure, mm Hg 105,1±15,6 
Diastolic blood pressure, mm Hg 87,2±10,9 
INR 2.11 ± 0.39 (1.48-3.00) 
One or more polymorphisms for VKORC1 or CYP2C9 (associated with 
warfarin sensitivity) were found in 32.0% of MCS/LVAD patients. 
By using a warfarin genotype-guided approach, LVAD patients with 
polymorphisms received a lower warfarin dosage to achieve a similar 
INR, with similar bleeding rates, in comparison with no polymorphisms. 
 A warfarin genotype-guided approach avoided excessive 
anticoagulation and its attendant bleeding risks. 
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Fig 1. Warfarin Polymorphism Genotype Profile of Patients 
in the Study 
Table 3. Clinical Outcomes of Patients in the Mutant (Abnormal 
Genotype) and Wild-Type (Normal Genotype) Groups 
Genotype  
Variable 
 
Mutant Type 
(Abnormal) 
N=32 
Wild Type (Normal) 
N=68 
P-value 
Warfarin daily 
dosage, mg 
3.2±1.5 5.5±3.7 
 
0.015 
INR 2.2±0.67 2.19±0.69 0.96 
Bleeding, number of 
patients,% 
5(15.6) 9(13.2) 
 
0.99 
Bleeding event rate 
(event/patient-year) 
6.13(4.91-7.55) 8.02(5.93-9.7) 0.13 
Table 3 shows the differences in INR, warfarin dosage, and bleeding 
events between the groups with and without one or more polymorphisms 
(mutations or abnormal warfarin genotypes).  
When compared with patients without genotype mutation, patients with 
mutations in the VKORC1 and CYP2C9 genes required a lower mean 
warfarin daily dosage to reach the same mean INR levels at discharge or 
before in-hospital mechanical support recovery, cardiac transplantation, 
or death. Patients in both groups had similar bleeding event rates for up 
to 18 months or before mechanical support recovery, cardiac 
transplantation, or death. 
At discharge or before composite end point, patients with any 
polymorphism received a lower mean warfarin dosage than patients 
having no polymorphism (3.2±1.5 vs. 5.5±3.7 mg, p = 0.015) and 
achieved a similar mean INR (2.20±0.67 vs. 2.19±0.69, p = 0.96). 
There was no significant difference in bleeding rates within 6-18 months 
or before composite end point (6.13 vs. 8.02 events/patient-year, p = 
0.13).  
 
No association between the presence of a polymorphism in the VKORC1 
and CYP2C9 genes and age, height, weight, or BMI in LVAD patients 
were observed.  
In multivariable analysis, there were no significant associations  etween 
polymorphism presence and any of the potential predictors including 
age, BMI, obesity, gender, ethnicity, cardiomyopathy type, or MCS type 
(data not shown; p > 0.05 for all). 
Demographic and clinical profiles of patients are shown in the Table 1. 
 
Warfarin Polymorphisms Genotype Profile of Patients in the Study with 
frequency of VKORC1 1639 G>A mutation, CYP2C9*2 (430 C>T; 
cytosine to thymine) and  the CYP2C9*3 (1075 A>C; adenine to 
cytosine) mutations are show in Fig 1. A total of 32.0% (32/100) of 
patients with implanted LVADs had at least one polymorphism: VKORC1 
(14.0%), CYP2C9*2 (15.0%), CYP2C9*2 and VKORC1 (3.0%).  
Anticoagulation therapy is required for patients with implanted LVADs to 
avoid thrombotic complications. All patients received standard 
anticoagulation therapy before and after implantation that included 
adjusted doses of warfarin to achieve the target INR (in most cases, the 
target INR value is 2.0-2.5 for HMII and HMIII devices, 3.0-3.5 for 
HeartWare HVAD), and antiplatelet therapy with aspirin. This therapy is 
adjusted individually for each patient to reduce the risk of ischemic 
stroke and bleeding. 
 
According to the study protocol, patients are observed within 6-18 
months after the implantation of LVAD. 
Cases of active bleeding after implantation of the LVAD were observed 
in only 14% (18 cases) of the total number of subjects. In the first month 
after implantation, there were only 5 cases of bleeding: 2 cases in the 
pleural cavity, 2 cases of gastrointestinal bleeding and 1 nosebleed. 
During the next 6 months after implantation of the device, 6 cases of 
active bleeding also occurred in 4 patients, including 4 cases of bleeding 
from the gastrointestinal tract, one case of gingival hemorrhage, and 
one – nasal bleeding. After 12 months after the operation, two cases of 
bleeding from the digestive tract were reported in two patients. After 18 
months of mechanical support of the left ventricle, 4 new cases of 
bleeding were observed, 1 case of repeated bleeding, all of them, 3 
cases - from the gastrointestinal tract, 1 – nasal bleeding, 1 - rectal 
bleeding. During the follow-up period, 12% of patients had a thrombosis 
of the pump (Table 2). 
Complication 
Number of 
events 
Number of 
patients 
% 
  
Bleeding 18 14 14 
Gastro-intestinal 11 9 9 
Nasal 3 3 3 
Pleural 2 2 2 
Other localization 2 2 2 
Pomp thrombosis 12 12 12 
Table  2. Bleeding and thrombosis complications in patients with 
LVADs implantation  during 18 month follow-up 
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